http://purl.org/np/RAiDNaBIhanAn_80pA1Iw-TCIshFcuS9zN-XJ4wpsu3CQ
.trig | .trig.txt | .jelly | .jelly.txt
@prefix biolink: <https://w3id.org/biolink/vocab/> . @prefix ns1: <https://w3id.org/np/o/ntemplate/> . @prefix this: <http://purl.org/np/RAiDNaBIhanAn_80pA1Iw-TCIshFcuS9zN-XJ4wpsu3CQ> . @prefix sub: <http://purl.org/np/RAiDNaBIhanAn_80pA1Iw-TCIshFcuS9zN-XJ4wpsu3CQ#> . @prefix schema: <https://schema.org/> . @prefix np: <http://www.nanopub.org/nschema#> . @prefix dct: <http://purl.org/dc/terms/> . @prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix orcid: <https://orcid.org/> . @prefix prov: <http://www.w3.org/ns/prov#> . @prefix npx: <http://purl.org/nanopub/x/> . sub:Head { this: a np:Nanopublication; np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo . } sub:assertion { <http://purl.obolibrary.org/obo/DOID_13550> biolink:category biolink:Disease . sub:association a rdf:Statement; rdf:object <http://purl.obolibrary.org/obo/DOID_13550>; rdf:predicate biolink:treats; rdf:subject <https://identifiers.org/drugbank:DB00747>; rdfs:label "\"Transderm Scop is contraindicated in the following populations: Patients with angle closure glaucoma. [ see Adverse Reactions (6)] Persons who are hypersensitive to the drug scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system. [see Drug Interactions (7) Description (11) Patients with angle closure glaucoma ( 4 6.2 Persons who are hypersensitive to scopolamine or to other belladonna alkaloids ( 4 7\""; biolink:provided_by <https://w3id.org/um/NeuroDKG>; biolink:relation schema:MedicalContraindication . <https://identifiers.org/drugbank:DB00747> biolink:category biolink:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "Pui3dnUHjZJvL1nGaibMRlKMe99gbyh7siVMli/+wx8R0uWx95ZSyvb0r8khENAg7cntu9v+S5v1bZgIk5zzqiTzZyTmSOxItHox29nHmY1duZlvQdFrr9MSAII8tLxp9l+Ayqz/xnatlo9FWP40Hmxc424Hn7t7hCDD2wjCpd4="; npx:hasSignatureTarget this: . this: dct:created "2021-08-25T14:24:27.593+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; ns1:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>; ns1:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>; ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> . }